REPLIMUNE GROUP, INC. Debt Securities, Available-for-sale, Unrealized Loss
REPLIMUNE GROUP, INC. (REPL) reported Debt Securities, Available-for-sale, Unrealized Loss of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-14
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-06-30 was $1.00K, a 98.70% decline year-over-year.
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $1.00K.
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was -$3.00K.
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was -$74.00K.
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for fiscal 2025 was $41.00K, a 73.55% decline from fiscal 2024.
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $155.00K, a 52.60% decline from fiscal 2023.
- REPLIMUNE GROUP, INC. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $327.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-14 | $2.00K derived: sum of 2 quarters · filed 2026-08-14 | -$1.00K derived: sum of 3 quarters · filed 2026-08-14 | -$75.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | -$2.00K derived: sum of 2 quarters · filed 2026-08-14 | -$76.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.00K 10-Q · filed 2026-08-14 |
| 2025-12-31 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03 | -$77.00K derived: sum of 2 quarters · filed 2026-02-03 | $0.00 10-Q · filed 2026-02-03 | |
| 2025-09-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | $3.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $77.00K 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $41.00K 10-K · filed 2026-06-29 | |||
| 2024-03-31 | $155.00K 10-K · filed 2024-05-16 | |||
| 2023-03-31 | $327.00K 10-K · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |